Completed in the fall of 2016, Summit Medical Group was the only practice in New Jersey to participate in SINUVA’s RESOLVE II Study of drug-eluting implants for chronic sinusitis patients with recurrent nasal polyps. The RESOLVE II Study is a randomized, sham-controlled, double-blind, multicenter study with 300 chronic sinusitis patients who had prior endoscopic sinus surgery but had returned with polyp regrowth. SINUVA is clinically backed by level 1-A evidence and has proven to reduce polyp disease by 74%, reduce nasal obstruction/congestion by 30%, and improve patients’ sense of smell. SINUVA was approved by the U.S. Food and Drug Administration (FDA) in December 2017.
Now, SMG’s Dr. Giant Lin, a rhinologist specializing in care of chronic sinus disease, is among the first physicians in the state to place SINUVA in patients. Placed during a routine office visit under local or topical anesthesia, SINUVA is designed to deliver an anti-inflammatory steroid directly to the site of disease for an extended period of time (up to 90 days) following placement into the sinus cavity. Prior to SINUVA, these patients often have no option besides repeating surgery again and again or continue to be steroid dependent for the rest of their lives. SINUVA offers a new, non-surgical solution unlike any other technology. SINUVA placement is performed in an office setting and takes about 15 minutes to be placed.
Publication of a pooled analysis of the RESOLVE and RESOLVE II randomized controlled trials (RCT) can be found in the American Journal of Rhinology & Allergy.